Literature DB >> 30760397

Cognitive Contributors to Multiple Errands Test (MET) Performance.

Melissa Hansen1, Nicole K De Amicis2, Nicole D Anderson3, Malcolm A Binns4, Amanda J Clark5, Deirdre R Dawson6.   

Abstract

OBJECTIVE: The Multiple Errands Test (MET) was designed to measure the effect of executive dysfunction on everyday life activities, but little is known about the cognitive requirements for successful performance. This study's objective was to investigate cognitive functions associated with successful MET performance, specifically, the Baycrest-MET.
METHOD: Correlation analysis examined relationships between Baycrest-MET performance and neuropsychological functioning in participants with acquired brain injury (ABI; N = 27).
RESULTS: The association of tasks omitted with executive function (EF) accounted for 15.2%-42.3% of the variance; the association of tasks omitted with attention and processing speed, for 16.8%-24.0%; and the association of tasks omitted and total rule breaks with visuospatial memory, for 18.5%-31.4%.
CONCLUSION: Poor performance on the Baycrest-MET in people with ABI is associated with impairments of EF, attention, memory, and processing speed. Different patterns of performance may arise from different constellations of impairments.
Copyright © 2018 by the American Occupational Therapy Association, Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30760397     DOI: 10.5014/ajot.2018.025049

Source DB:  PubMed          Journal:  Am J Occup Ther        ISSN: 0272-9490


  2 in total

1.  Developing and Validating a Big-Store Multiple Errands Test.

Authors:  Kristen Antoniak; Julie Clores; Danielle Jensen; Emily Nalder; Shlomit Rotenberg; Deirdre R Dawson
Journal:  Front Psychol       Date:  2019-11-15

2.  Daily Activities: The Impact of COPD and Cognitive Dysfunction.

Authors:  Amanda M Brunette; Kelsey Warner; Kristen E Holm; Kimberly Meschede; Frederick S Wamboldt; Elizabeth Kozora; David J Moser; Barry J Make; James D Crapo; Kerrie L Moreau; Howard D Weinberger; Russell Bowler; Karin F Hoth
Journal:  Arch Clin Neuropsychol       Date:  2021-07-19       Impact factor: 2.813

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.